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COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN
COMBINATION WITH RADIOTHERAPY VERSUS
RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY
ADVANCED HEAD AND NECK CANCER IN FRANCE
Brown B1, Robinson P1, Launois R2, Griebsch I3
1IMS Health, London, UK, 2REES, Paris, France, 3Merck KGaA,
Darmstadt, Germany
OBJECTIVE: To estimate the cost-effectiveness of cetuximab in
combination with radiotherapy (ERT) compared to radiotherapy
alone (RT), for the treatment of locally advanced head and neck
cancer in patients for whom chemoradiotherapy is inappropri-
ate or intolerable in France. METHODS: A modelled economic
evaluation calculated the incremental cost per quality-adjusted
life year (QALYs) gained with ERT compared to RT. Resource
utilisation and survival data were extracted from an interna-
tional phase-III trial of ERT. Assumptions regarding costs of care
were drawn from estimates by an expert clinical panel. Overall
survival and progression-free survival times were extrapolated
beyond the trial period using statistical models. Patient survival
was stratiﬁed into health states deﬁned by adverse event status
in the acute phase and disease status post-treatment. Utility
values for the health states were obtained from a survey of oncol-
ogy nurses using the EQ-5D. Estimates of individual costs and
outcomes were estimated for each patient in the trial and overall
mean values calculated for the incremental analysis between the
treatment groups. The analysis was conducted from the per-
spective of the public and private French healthcare system.
Costs and outcomes were discounted at 3.5%. RESULTS: In the
lifetime analysis, ERT patients were estimated to gain an extra
1.07 QALYs compared to RT patients. From the public estab-
lishment perspective, this translated into an incremental cost per
QALY gained of €10,927. Shortening the analysis to the time-
frame of the clinical trial (5 years) raised the ICERs to €31,355
per QALY gained respectively. Bootstrap simulation and sensi-
tivity analysis showed that the ICERs were robust to changes in
the key variables. CONCLUSIONS: Results of the modeled eco-
nomic evaluation strongly suggest that ERT offers a good value-
for-money alternative in the treatment of locally advanced head
and neck cancer in France.
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COST UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS WITH
PEGFILGRASTIM VERSUS FILGRASTIM FOR BREAST CANCER
IN THE UK
Booth P1, Dubois R2, Doan QV2, Liu Z2
1Amgen Ltd, Cambridge, UK, 2Cerner Health Insights, Beverly Hills,
CA, USA
OBJECTIVES: Primary (ﬁrst and subsequent cycles) prophylaxis
with colony stimulating factors is recommended in the 2006
ASCO and EORTC clinical guidelines when the risk of febrile
neutropenia (FN) is ≥20%. In clinical practice, ﬁlgrastim has
often been used for fewer than the recommended 11 days, which
has been shown to compromise clinical outcomes. This study
evaluated the cost-utility of pegﬁlgrastim vs. ﬁlgrastim (11- or 6-
days) primary prophylaxis in women with breast cancer receiv-
ing chemotherapy with ≥20% FN risk in the UK. METHODS:
We constructed a decision-analytic model from a payer’s per-
spective. Costs were from ofﬁcial list prices or literature and
included drugs, drug administration, FN-related hospitalisations
and subsequent medical costs. FN risk (varied by days of ﬁl-
grastim), FN case-fatality, relative dose intensity (RDI), the
impact of RDI on survival, and utility scores were based on a
comprehensive literature review and expert panel validation.
Breast cancer mortality and all-cause mortality were obtained
from ofﬁcial statistics. Model robustness was tested using multi-
way sensitivity analyses. RESULTS: Pegﬁlgrastim was cost-
saving in addition to being more effective than 11-day ﬁlgrastim.
Compared with 6-day ﬁlgrastim, pegﬁlgrastim achieved 0.107
more QALYs (15.139 vs. 15.032 QALY) at a minimal cost
increase of ≤446 (≤3193 vs. ≤2747) per person; the incremental
cost-utility ratio was ≤4166/QALY. Pegﬁlgrastim decreased the
absolute risk of FN by 10.5% (17.5% vs. 7%), and was associ-
ated with ≤4246 per FN avoided or ≤42 per 1% decrease in
absolute risk of FN. Age of diagnosis and cancer stage had
minimal impact on the results. The results were sensitive to 
the costs of drugs and risk of FN. CONCLUSIONS: Use of 
pegﬁlgrastim in the UK appeared to dominate 11-day use of 
ﬁlgrastim. The value of pegﬁlgrastim vs. 6-day ﬁlgrastim 
at ≤4166/QALY is very favourable compared with the cost-
effectiveness threshold commonly used in the UK HTA setting.
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COST EFFECTIVENESS OF ADDING IMATINIB TO
CHEMOTHERAPY IN ADULT PATIENTS WITH PHILADELPHIA
CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIA (PH+ALL):AN EXPLORATORY ANALYSIS FOR 
THE UK
Botteman MF,Tran KT, Stephens JM
PharMerit North America LLC, Bethesda, MD, USA
OBJECTIVES: Imatinib combined with conventional
chemotherapy (CC) in Ph+ALL patients has produced encourag-
ing efﬁcacy results with a well-tolerated safety proﬁle. This study
explores the cost effectiveness of imatinib plus CC versus CC
alone in adult Ph+ALL patients. METHODS: A Markov model
simulated a hypothetical cohort of adult Ph+ALL patients receiv-
ing imatinib plus CC or CC alone. The model included three
states: alive without disease progression (DFS), alive with disease
progression (DS), and death. State transition probabilities were
derived from the published literature. In the absence of relevant
data pertaining to Ph+ALL, assumptions about costs and utilities
were derived from a cost analysis of CML. Only direct medical
costs were included, adopting a UK health care payer perspec-
tive. All outcomes were discounted. An adaptation of the model
to the US perspective was conducted as well. RESULTS: The
model projects that the total discounted survival was 1.10 years
for CC and 4.31 years for imatinib+CC. Total discounted disease
free survival was 0.76 year for CC and 2.77 years for ima-
tinib+CC. The total discounted quality adjusted life years
(QALY) were 0.85 v. 3.28 for CC and imatinib+CC, respectively.
Thus, the net incremental gain in discounted quality adjusted
survival was 2.43 QALYs. The monthly costs of DFS and DS
were estimated at £123 and £417, respectively. The net costs
associated with imatinib were £51,757 for the UK. The incre-
mental cost per QALY of imatinib+CC v. CC alone was approx-
imately £21,290 (i.e., £51,757 divided by 2.43 QALYs).
Adapting the model to the US perspective, the incremental cost
per QALY was about $42,000. CONCLUSIONS: For adult ALL
patients with poor prognosis due to Ph+ALL, our exploratory
analysis suggests that, given the underlying data and assump-
tions, adding imatinib to current chemotherapy regimens is cost-
effective compared to chemotherapy alone both from the UK and
the US perspectives.
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EPOIETIN ALPHA TREATMENT FOR CANCER PATIENTS WITH
CHEMOTHERAPY INDUCED ANAEMIA—A COST-
EFFECTIVENESS ANALYSIS FOR SWEDEN
Borg S, Glenngård AH, Persson U
The Swedish Institute for Health Economics, IHE, Lund, Sweden
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Anaemia is a common complication of chemotherapy. Since
anaemia can lead to different symptoms, such as fatigue, respi-
ratory distress and chest pain, thereby diminishing physical
capacity and quality of life, it is generally accepted that anaemia
should be corrected. Treatment options include red blood cell
transfusion (RBCT), erythropoietin (EPO) administration or a
combination of both. OBJECTIVE: Our objective was to carry
out a cost-effectiveness analysis of treatment with EPO (ery-
thropoietin alpha) compared to traditional treatment with RBCT
for patients with chemotherapy-induced anaemia in Sweden
from a hospital perspective. METHOD: We developed a model
for Swedish treatment practice (patient characteristics, response
rates, and RBC transfusion data taken from Swedish observa-
tional data), and Swedish unit costs, based on a model commis-
sioned by the National Institute of Clinical Excellence, UK.
Incremental costs associated with EPO treatment compared to
treatment with RBCT, were estimated. Different cancer types and
populations were modelled by varying initial Hb, response and
mortality rates. RESULTS: The model results on costs corre-
spond well to real world data from three big hospitals in Sweden.
Average costs per patient are SEK34,900 for EPO and SEK
12,400 for RBCT. The cost per QALY gained from admini-
stration of EPO assuming a survival beneﬁt attributable to EPO
treatment was estimated at SEK 120,000. The survival beneﬁt
from EPO is debated, and has a major impact of the results.
Excluding this beneﬁt gives an estimated cost of SEK 365,000
per QALY. EPO treatment is most cost-effective in patients with
initial Hb of 9–10 g/dl. The cost-effectiveness-ratio is also 
moderately sensitive to changes in the response rate to EPO,
baseline mortality, the cost of EPO and the estimated QALY gain 
from EPO administration. CONCLUSION: The estimated cost
per QALY falls well within the range acceptable in Sweden. 
The cost-effectiveness of EPO varies between different cancer
populations.
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COUNTY LEVEL INEQUALITIES IN THE ATTENDANCE OF
THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL
CANCER SCREENING PROGRAMME
Boncz I1, Sebestyén A1, Döbrõssy L2, Budai A2, Betlehem J3, Ember I3
1National Health Insurance Fund Administration (OEP), Budapest,
Hungary, 2National Public Health and Medical Ofﬁcers Service
(ÁNTSZ), Budapest, Hungary, 3University of Pécs, Pécs, Hungary
OBJECTIVES: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. Women
between the ages 25–65 are invited by a personal letter and a 3
years screening interval has been applied. Before the implemen-
tation of organized screening programme there was an oppor-
tunistic screening. The aim of this study is to analyse the three
year screening rate (attendance or coverage) of the organized
programme according to counties. METHODS: The data derive
from the ﬁnancial database of the National Health Insurance
Fund Administration (OEP) of Hungary covering the period 
of 2000–2005. We calculated the three-year screening rate of 
two periods: 2000–2002 without and 2003–2005 with organized
screening programme for women aged 25–64. Screening is
deﬁned with cytological examination of Papanicolau smear and
includes all smears taken either within or outside of the orga-
nized programme. RESULTS: The age speciﬁc screening rate of
women aged 25–64 years increased from 48, 45% in 2000–2002
without organized screening programme to 52, 65% in
2003–2005 following the introduction of organized screening
programme. There were signiﬁcant differences in the screening
rate (attendance or coverage) among counties with the highest
values in county Baranya (58, 59%), Tolna (55, 35%), Borsod-
Abaúj-Zemplén (54, 61%) and the lowest values in county 
Jász-Nagykun-Szolnok (40, 06%), Vas (41, 47%), Veszprém (42,
52%). From 2000–2002 to 2003–2005 we found the largest
increase in the following counties: Veszprém (14.35 percent
point), Borsod-Abaúj-Zemplén (7.69 percent point), Békés (5.46
percent point). The gap between the counties with the highest
and lowest screening rate decreased. CONCLUSIONS: We
found signiﬁcant differences in the screening rate among coun-
ties, which should be reduced. However, the introduction of
organized cervical screenig programme lead to closing up the
between county differences.
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A MODEL FOR PROJECTING BOWEL CANCER INCIDENCE
AND MORTALITY: APPLICATION TO THE UK BOWEL
CANCER SCREENING PROGRAM
Muston D1, Howard PA1, Lee DW2
1Heron Evidence Development Ltd, Letchworth, Herts, UK, 2GE
Healthcare, Waukesha, WI, USA
OBJECTIVES: To develop a simulation model for estimating the
future impact on deaths and new bowel cancer registrations
under alternative bowel cancer screening programme implemen-
tation and design strategies. METHODS: The UK began phasing
in a faecal occult blood test (FOBT) bowel cancer screening pro-
gramme for all persons aged 60–69 in April 2006. We ﬁtted a
novel Bayesian autoregressive age-period-cohort model (Bray
2002) to bowel cancer incidence and mortality data in England
1993–2003/4 (ONS/GAD 2005) that uses parameters efﬁciently
and provides credible intervals for assessing projection uncer-
tainty. We then used the model with results taken from separate
cohort-based bowel cancer natural history modelling (Tappen-
den 2004) and government age- and gender-speciﬁc population
projections to estimate bowel cancer incidence and mortality for
2003–2016 under various bowel cancer screening program
design and implementation strategies. RESULTS: The model ﬁt
the data well. We estimate that phased implementation of the
UK bowel screening program will result in 2440 undetected
cancers (95% CI 808–10,160) and 244 (95% CI 114–610) addi-
tional bowel cancer deaths in 2006–8. Further, a programme
combining FOBT with ﬂexible sigmoidoscopy would detect an
estimated 737 (95% CI 207–3917) more bowel cancers and
prevent 389 (95% CI 156–1168) more deaths than FOBT alone.
CONCLUSIONS: This model provides a valuable tool for 
generating point and interval estimates of the long-term popu-
lation impact of alternative bowel cancer screening program
implementation and design strategies, and can be updated as 
new information arises. Projection uncertainty arises from the
model itself and the disease natural history information used to
inform it.
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FACTORS INFLUENCING INEQUITABLE ACCESS TO
RADIATION THERAPY: THE CASE STUDY OF CANCER
PATIENTS IN THAILAND
Prakongsai P1, Chunharas S2,Tangcharoensathien V1
1International Health Policy Program—Thailand, Nonthaburi,Thailand,
2National Health Foundation, Bangkok,Thailand
OBJECTIVES: To describe factors inﬂuencing inequitable access
to radiation therapy among cancer patients in Thailand by
exploring the current situation and problems of both demand
and supply sides after implementation of the policy on universal
coverage. The study aimed to improve efﬁciency in health
resource allocation and equitable access to expensive health ser-
vices by using radiation therapy as the case study. METHODS:
